# ALK-Abelló ACARIZAX Phase 3 Trial Meets Primary Endpoint in China

- URL: https://stocks.freetheai.org/news/alk-abello-acarizax-phase-3-trial-meets-primary-endpoint-in-china-38504b
- Published: 2026-10-19T13:29:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [OMXCOP:ALK_B](https://stocks.freetheai.org/symbols/OMXCOP-ALK_B)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

ALK-Abelló A/S (OMXCOP:ALK_B) announced that its Phase 3 bridging trial in China for house dust mite allergy treatment ACARIZAX successfully met its primary endpoint. The trial, which included 327 participants over a period of 24 to 28 weeks, showed a 1.11 total combined response score difference compared to placebo, representing a 19.1% improvement. The treatment's safety profile remained consistent with results from previous clinical studies.

The positive outcome clears a key clinical hurdle for the company to expand into China's allergy treatment market. Following the announcement, Class B shares of ALK-Abelló A/S gained 2.46% to trade at 233 DKK. Management confirmed that its full-year financial outlook for 2026 remains unchanged, as the near-term financial impact is limited ahead of potential commercial entry.

Moving forward, ALK-Abelló plans to use the Phase 3 data to support a local regulatory application in China alongside its partner, GenSci. Investors will monitor the regulatory submission process and progress toward eventual market authorization and reimbursement.

## Key points

- ALK-Abelló's Phase 3 bridging trial for ACARIZAX in China met its primary endpoint in house dust mite allergy.
- The study demonstrated a 1.11 score difference, or a 19.1% improvement over placebo, across 327 participants.
- Safety results were consistent with prior clinical trial data over the 24- to 28-week study duration.
- ALK-Abelló plans to submit a local regulatory filing in China with partner GenSci while keeping 2026 guidance unchanged.
- Shares of ALK-Abelló A/S Class B (OMXCOP:ALK_B) rose 2.46% to 233 DKK following the release.

## Questions and answers

### What were the key results of ALK-Abelló's Phase 3 trial in China?

The trial met its primary endpoint for ACARIZAX in house dust mite allergy, showing a 1.11 total combined response score difference (19.1% improvement) over placebo with a safety profile consistent with prior data.

### What is the next step for ACARIZAX in China?

ALK-Abelló plans to use the Phase 3 trial findings to support a local regulatory filing for ACARIZAX in China in partnership with GenSci.

### How did ALK-Abelló's stock react to the trial results?

Shares of ALK-Abelló A/S Class B (OMXCOP:ALK_B) rose 2.46% to 233 DKK following the trial update.